Emerging research suggest Retatrutide , a dual agonist targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , could provide a significant advancement for body loss . Early patient trials have demonstrated considerable decreases in visceral mass , potentially exceeding current weight-loss medications . Despite this, mor